Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.

By M. Copland, A. Hamilton, Lucy J. Elrick, J. W. Baird, E. Allan, N. Jordanides, M. Barow, J. Mountford, T. Holyoake. Blood, 2006

700 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/8c1448fa9888e806068fc6f13f2b9856f2f76a23

Citations in the corpus

• Targeting cancer with small molecule kinase inhibitors (2009, unknown): “Additionally, it has been shown in several haematological tumours that quiescent stem cells are refractory to tyrosine kinase inhibitors, and these cell populations are probably also involved in resistance mechanism”